Flunitrazepam, a new benzodiazepine compound in general anaesthesia. Clinical and statistical considerations on the first thousand cases.
Flunitrazepam, a derivative of benzodiazepine was used for induction and maintenance of anaesthesia in 933 patients. The induction dose was from 1,786 to 2,053 mg. The total dose of 2-2.66 mg was sufficient for maintenance of hypnosis for about 2 hours. The undesirable side effects were very rare. The average time of hypnosis after a single dose of flunitrazepam was 50.1 sec. The sedative action of the drug lasted for some time after regaining of consciousness. In most patients there was no need for administration of analgetics during first 24 hours after the operation. The authors believe that surgical anaesthesia will greatly benefit from this drug.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000768:Anesthesia, General; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005445:Flunitrazepam / Q000494:pharmacology*; D006801:Humans; D006991:Hypnosis, Anesthetic; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects; D010146:Pain; D010423:Pentazocine / Q000494:pharmacology; D011229:Preanesthetic Medication; D012018:Reflex / Q000187:drug effects; D012137:Respiratory System / Q000187:drug effects
D014151:Anti-Anxiety Agents; D005445:Flunitrazepam; D010423:Pentazocine